LOS ANGELES, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On August 7, 2025, Ta ...

AdaptHealth Conference Call Summary Company Overview - **Company**: AdaptHealth (Ticker: AHCO) - **Industry**: Durable Medical Equipment (DME) - **Key Segments**: CPAP for obstructive sleep apnea (OSA), diabetes management, respiratory therapies, and wellness at home [2][3] Key Points and Arguments Market Position and Growth - AdaptHealth is the largest DME operator in the U.S., supplying approximately 25% of the 6-7 million patients treated for OSA [3] - The market for OSA is underpenetrated, with estimates of 33-34 million Americans affected, indicating significant growth potential [3] - In Q2 2025, AdaptHealth set up 128,000 new CPAP patients, reflecting over 3% growth year-over-year [3] Business Segment Performance - **Sleep Segment**: Expected to maintain mid-single-digit growth, potentially reaching 5% if diabetes returns to growth [4] - **Respiratory Segment**: Anticipated growth of 3-3.5%, with current performance exceeding expectations despite a softer flu season [4] - **Diabetes Segment**: After operational changes, the segment is showing improvement with record retention levels, aiming to return to growth mode [5] - **Wellness at Home**: Completed two significant dispositions in Q2, using proceeds to reduce debt [6] Financial Outlook - Top-line organic revenue growth is projected at 3-4%, with potential contributions from tuck-in M&A [7] - A significant contract with a major healthcare system is expected to generate at least $200 million annually, with adjusted EBITDA margins of 20-21% [8] - Anticipated improvements in EBITDA due to accounting changes and cost reductions from AI and automation investments [9][10] Competitive Landscape and Regulatory Environment - The DME market is expected to consolidate further, with competitive bidding reducing the number of operators [13][19] - AdaptHealth believes it is well-positioned to win contracts in the upcoming competitive bidding rounds, with a focus on service level agreements to enhance payer relationships [14][16] - The diabetes segment will face new competitive pricing dynamics, with fewer operators expected to win contracts [21][22] Innovation and Market Dynamics - Concerns exist regarding alternative therapies impacting CPAP usage, but demand for sleep apnea treatment remains strong [37][39] - The company is monitoring the impact of new technologies and wearables on patient detection and adherence [38] Cash Flow and Capital Deployment - Free cash flow generation is projected to remain between 6-7% of revenue, with ongoing debt reduction and modest M&A activities planned [44] - The company aims to achieve a leverage target of 2.5 times EBITDA by mid-2026 [43] Investor Insights - The transformation towards increased free cash flow generation is a key focus, with strategic dispositions aimed at improving financial health [48][50] - Anticipated tax benefits from equipment purchases and bonus depreciation will enhance cash flow in the coming years [50] Additional Important Points - AdaptHealth's competitive advantage lies in its scale and technology, allowing it to offer better service and pricing compared to smaller operators [15][16] - The company is committed to continuous improvement in service delivery and operational efficiency [14][15] - The management team has undergone significant changes to enhance performance in the diabetes segment, with a focus on sales and retention strategies [33][34]

Summary of the Conference Call Company Overview - **Company Name**: Inbecta - **Background**: Inbecta was spun out from Becton Dickinson's diabetes business on April 1, 2022, and has been a public company for over three years. The company generates approximately $1 billion in revenue and operates in around 140 countries with three main product categories: pen needles, safety products, and syringes [3][4]. Financial Performance and Growth Drivers - **Revenue Composition**: About 85% of Inbecta's revenue comes from pen needles and safety products, which have been growing at a rate of 2% to 2.5% over the past few years [4]. - **Financial Goals**: The company set a revenue CAGR target from 2022 to 2024 that was expected to be flat, with an adjusted EBITDA margin of around 30%. Inbecta exceeded both metrics during this period despite facing significant inflationary impacts [5][6]. - **Future Projections**: The core injection business is projected to experience a 1% to 2% CAGR decline over the long-range planning (LRP) period, primarily due to pressures in the US syringe business and a transition to other technologies [7][9]. Market Dynamics - **Syringe Business Challenges**: The US syringe business is under pressure, with expectations that revenue from this segment could decline significantly by 2028 [10]. - **Emerging Markets Growth**: Emerging markets, which represent about 20% of the business, are expected to grow at mid-single digits, while developed markets may see slight declines [12]. New Revenue Streams and Product Development - **New Product Opportunities**: Inbecta is focusing on leveraging its manufacturing capabilities and distribution agreements to introduce new products, including blood glucose monitors (BGMs), insulin pumps, and ultrasound products [15][17][27]. - **GLP-1 Market Potential**: The company is exploring partnerships with generic pharmaceutical companies for GLP-1 products, which could represent a $100 million annual market opportunity by 2033 [20][21]. Financial Strategy and Cash Flow - **Free Cash Flow Generation**: Inbecta anticipates generating approximately $600 million in cumulative free cash flow over the LRP period, with plans to pay down at least $110 million in debt in 2025 [35][36]. - **Debt Management**: The company aims to reduce its net leverage to around three times by the end of 2025, with potential for further reductions by 2028 [39][40]. Margin and Cost Considerations - **Operating Margin Decline**: The adjusted operating margin is expected to decline by approximately 125 basis points due to incremental tariffs and increased R&D expenses related to sourcing cannulas from multiple suppliers [28][29][31]. - **Tariff Impact**: Incremental tariffs are estimated to impact the business by $9 million to $10 million annually, but most products are largely exempt from tariffs due to medical necessity [43]. Key Takeaways - **Underappreciated Aspects**: The free cash flow capabilities of Inbecta have been masked by the complexities of separation from Becton Dickinson. The company is poised for growth through new product introductions and strategic partnerships [45][46].